Studies in mouse models of Fragile X and preliminary studies in human youth demonstrate that ERK1/2 is biomarker useful to monitoring the treatment of people diagnosed with ASD. Results reported herein demonstrate that acamprosate has the ability to reduce levels of ERK1/2 activation associated with many of the symptoms of ASD. Accordingly, in addition to its utility as a diagnostic marker for ASD ERK1/2 activation levels can be used to monitor patients treated with acamprosate and to screen potentially therapeutic compounds.

Provided are a recombinant CHO cell, a construction method therefor, a detection system containing same, and a detection method using same. The recombinant CHO cell stably expresses NGF on the cell surface thereof and can be used as a target cell for an ADCC effect assay and a CDC effect assay.

Studies in mouse models of Fragile X and preliminary studies in human youth demonstrate that ERK1/2 is biomarker useful to monitoring the treatment of people diagnosed with ASD. Results reported herein demonstrate that acamprosate has the ability to reduce levels of ERK1/2 activation associated with many of the symptoms of ASD. Accordingly, in addition to its utility as a diagnostic marker for ASD ERK1/2 activation levels can be used to monitory patients treated with acamprosate.

A method for diagnosing of or for determining the risk of developing Alzheimer's disease, as well as for determining the presence of severe AD in a subject involves at least four specific biomarkers being measured. A kit or an array comprising a detecting means, in particular antibodies, for at least four specific biomarkers can be used for the diagnosis. Further, a computer program product and a computer implemented method for diagnosing of or determining the risk of developing Alzheimer's disease may be employed.

A BDNF quantitative immunochromatographic test strip and its preparation method, comprises: a substrate and a coated film, on which a sample pad, a coated line area and a water-absorbing pad are arranged; the coated line area comprises a marking line, a detecting line and quality control line, which are arranged in parallel and separated from each other, the marking line is arranged close to the sample pad, the detecting line is arranged between the marking line and the quality control line, the quality control line is arranged close to the water-absorbing pad; the marking line is the marking line coated with fluorescent microspheres marked with first BDNF monoclonal antibody and quality control antigen or antibody, the quality control line is the quality control line coated with quality control antibody or antigen, and the detection line is the detection line coated with second BDNF monoclonal antibody.

The present invention provides a method of inhibiting tumor progression in a subject suffering from VGF expressing cancers. The present invention also provides a method and a kit of predicting or determining tumor progression state in a subject suffering from VGF expressing cancers.

Method for the early diagnosis and the monitoring of the evolution/regression of neurodegenerative pathologies, said method providing for the quantification of a, biomarker for said pathologies in a fluid that was previously drawn from a, patient, said fluid being selected from among: cerebrospinal fluid; serum; urine; post mortem cerebral tissues and cellular lysates, said method being characterized in that the quantified biomarker is selected from among native proNGF; modified proNGF, the latter being proNGF in its forms with higher molecular weight, including forms of 39-40 kDa and 45-50 kDa; NGF; and the proNGF/NGF ratio, said method sequentially providing for the following steps of Preparation of the biological sample. Definition of the calibration curve: Execution of run and interpolation.

The present disclosure provides TrkA antibodies, compositions comprising such antibodies, and methods of using such antibodies for the prevention and/or treatment of a disease or disorder associated with an inappropriate expression or function of TrkA, such as pain.

The present invention discloses a monoclonal antibody against nerve growth factor, and an encoding gene and use thereof. The monoclonal antibody comprises heavy chains comprising a heavy chain constant region and a heavy chain variable region, and light chains comprising a light chain constant region and a light chain variable region. The heavy chain variable region comprises three complementarity determining regions HCDR1, HCDR2 and HCDR3, and the light chain variable region comprises three complementarity determining regions LCDR1, LCDR2 and LCDR3. The monoclonal antibody can specifically bind to nerve growth factor, and can be used to detect the presence and/or level of nerve growth factor, as well as to prepare a drug for inhibiting the nerve growth factor-dependent proliferation of TF-1 cells, and for treating or preventing at least one of neuropathic pain, chronic pain, and inflammatory pain, thus having good application prospects and marketing value.

The present disclosure provides a whole blood, protein-based diagnostic test for presence and evaluation of aneurysm status. Further, the present disclosure relates to methods of treating aneurysms.